港股異動丨維他奶跌逾4% 業績大幅下滑 首次不派中期息
格隆匯11月26日丨維他奶跌逾4%,報17.6港元,總市值188億港元。維他奶昨日午間公佈截至9月30日止6個月的中期業績,期內,集團實現收入36.04億港元,同比下降18.3%;毛利17.27億港元,同比下降28.3%,毛利率由上年同期的55%跌至48%;公司股權持有人應占溢利3280.4萬港元,同比下降95.1%維他奶自1994年上市以來,首次不派中期息,維他奶雖然股息率不算高,但勝在派息夠穩定,維他奶於業績報吿指,由於業績不理想,必須先恢復內地業務表現,不派中期息。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.